Brokerages expect that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.17). Sunesis Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which indicates a positive year-over-year growth rate of 43.2%. The company is expected to issue its next earnings report on Thursday, March 8th.
On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.48). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Sunesis Pharmaceuticals.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same quarter last year, the business posted ($0.62) earnings per share.
In related news, major shareholder Mpm Oncology Impact Management purchased 25,300 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were acquired at an average price of $2.59 per share, with a total value of $65,527.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average price of $2.00 per share, for a total transaction of $800,000.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 506,800 shares of company stock worth $1,091,282. Company insiders own 10.21% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of SNSS. Wells Fargo & Company MN increased its position in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at $208,000. Vanguard Group Inc. increased its position in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the period. Finally, Balyasny Asset Management LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at $5,400,000. Hedge funds and other institutional investors own 38.21% of the company’s stock.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.01 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45. The stock has a market capitalization of $136.96, a PE ratio of -2.29 and a beta of 1.53.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.